Literature DB >> 30977095

Straightening out the wrinkles in technetium-99m-labeled bone scintigraphy tracer assessment of cardiac amyloidosis.

Gary R Small1, Terrence D Ruddy2.   

Abstract

Entities:  

Year:  2019        PMID： 30977095     DOI： 10.1007/s12350-019-01718-8

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  2 in total

1.  PYP or DPD and HDP for cardiac amyloidosis one for all, all for one.

Authors:  Francesco Cappelli; Chiara Gallini; Federico Perfetto
Journal:  J Nucl Cardiol       Date:  2019-05-01       Impact factor: 5.952

2.  State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis.

Authors:  Vasvi Singh; Rodney Falk; Marcelo F Di Carli; Marie Kijewski; Claudio Rapezzi; Sharmila Dorbala
Journal:  J Nucl Cardiol       Date:  2018-12-19       Impact factor: 5.952
  2 in total
  3 in total

1.  A case report of an uncommon presentation of 99mtechnetium pyrophosphate scintigraphy in transthyretin cardiac amyloidosis: A potential diagnostic pitfall, pseudo-positive or pseudo-negative?

Authors:  Yuri Ochi; Toru Kubo; Yasuteru Nakashima; Asa Takahashi; Yuichi Baba; Takayoshi Hirota; Naohito Yamasaki; Hiroaki Kitaoka
Journal:  J Cardiol Cases       Date:  2019-10-08

2.  Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation.

Authors:  Claire Cuscaden; Stuart C Ramsay; Sandhir Prasad; Bruce Goodwin; Jye Smith
Journal:  J Nucl Cardiol       Date:  2020-05-08       Impact factor: 5.952

Review 3.  Renal amyloidosis: a new time for a complete diagnosis.

Authors:  V A Feitosa; P D M M Neves; L B Jorge; I L Noronha; L F Onuchic
Journal:  Braz J Med Biol Res       Date:  2022-10-03       Impact factor: 2.904
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.